Strategic Communication and Public Relations

Second European Conference on Epigenetics and Cancer

No. 24c | 09/05/2017 | by Koh

From May 11th to May 13th the German Cancer Research Center is hosting the Second European Conference on Epigenetics and Cancer. About 200 scientists from all over the world will be exchanging views on how small chemical changes in DNA or in their packaging proteins contribute to cancer development, how they could improve cancer diagnosis, or even how they could serve as the target for new cancer therapies.

© Schuster/DKFZ

In addition to genetic information that is embedded in the DNA base sequence, there is a second code of life: chemical changes in DNA or in their packaging proteins, the histones, form an additional control level which determines which genes are actually read. This "epigenetic" code has a decisive influence on all cellular processes – and therefore also on whether a cell develops into a cancer cell.

"The research projects that are concerned with the connection between epigenesis and cancer have become quite numerous. It's high time we provided a platform for this topic via regular conferences so that we can facilitate the exchange of ideas," says Christoph Plass from the German Cancer Research Center (DKFZ), one of the organizers of the event. His DKFZ colleague Karsten Rippe, also one of the organizers, adds: "The conference will from now on be held every two years and will cover the field in its entirety."

A whole section of the conference is concerned with the question of how changes in the epigenetic code can disrupt the carefully balanced interplay of cellular signal pathways and therefore facilitate cancer growth. Joseph Costello from the University of San Francisco describes how genetic and epigenetic mutations develop almost in tandem and in close proximity to each other while brain tumors transition from benign to malignant, and eventually allow the cell to degenerate altogether.

The epigenetic programming is crucial to the identity of a cell. Frank Lyko of the DKFZ examines this point in his talk. He has discovered indications that various subtypes of colon cancer from different original cells originate in the intestinal mucosa. This could allow for the specific DNA-Methylation patterns of the cells to be used for the exact classification of colon tumors.

Toshikazu Ushijima of the National Cancer Research Institute in Tokyo sees epigenetic patterns as helpful biomarkers: With certain types of cancer, such as a neuroblastoma or stomach cancer, these patterns could be used to predict the further development of the illness.

In countless questions, cancer epigenesis has left basic research behind and scientists are already applying their knowledge into practical clinical applications. Stephen B. Baylin of the Johns Hopkin University School of Medicine, Baltimore, is one of the pioneers in this field. He reports various approaches of utilizing epigenetic changes in tumors as target structures for new cancer therapies. Other projects are already in the clinical test phase. Olaf Witt, of the DKFZ and Heidelberg University Hospital, has already reported completing a clinical study. It tested the efficacy of the epigenetically functioning medication Vorinostat on leukemia and solid tumors with children – the analysis of the trial will follow soon.

Journalists are cordially invited to attend the conference.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS